杜皮鲁玛
医学
哮喘
特应性皮炎
恶化
临床试验
免疫学
随机对照试验
单克隆抗体
单克隆
内科学
抗体
作者
Alice Grey,Constance Helen Katelaris
出处
期刊:Immunotherapy
[Future Medicine]
日期:2019-06-20
卷期号:11 (10): 859-872
被引量:26
标识
DOI:10.2217/imt-2019-0008
摘要
Dupilumab is a fully human monoclonal IgG4 antibody that blocks IL-4 and IL-13 signaling. Its efficacy has been assessed across a range of atopic diseases, due to its ability to inhibit T helper cell 2 (Th2) mediated inflammation. It has already been approved in the USA and Europe for the treatment of atopic dermatitis. Recently, it also gained approval in the USA as add-on treatment for moderate-to-severe asthma in adolescents and adults. Phase II and III randomized controlled trials have demonstrated improvements in asthma exacerbation rates, FEV1, oral glucocorticoid use and a range of patient-reported outcomes, with a favorable safety profile. This article will review the available clinical trial data relating to the efficacy and safety of dupilumab in the management of asthma and related atopic respiratory conditions.
科研通智能强力驱动
Strongly Powered by AbleSci AI